GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

Things are, however, looking good for its latest launch, respiratory syncytial virus vaccine Arexvy, which GSK thinks can reach around $4 billion in annual sales. Zealand Pharma has suffered ...

Eliminating fake vaccine news with pharmacist, nurse, and physician review. According to the Pan American Health Organization (PAHO) chikungunya data dashboard, the Federative Republic of Brazil has ...